Compare
NRX Pharmaceuticals, Inc. vs Avenue Therapeutics, Inc. vs Northwest Biotherapeutics Inc vs Cannapharmarx, Inc.
| Latest fiscal year | NRX Pharmaceuticals, Inc. NRXP | Avenue Therapeutics, Inc. ATXI | Northwest Biotherapeutics Inc NWBO | Cannapharmarx, Inc. CPMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.45M | $1.40M | $1.38M | $1.36M |
| Revenue growth (YoY) | n/a | n/a | -0.3% | +66.1% |
| Gross margin | 65.1% (computed) | n/a | n/a | -153.1% |
| Operating margin | n/m | -219.6% | n/m | -245.8% |
| Net margin | n/m | -207.2% | n/m | -817.2% |
| Net income | -$28.62M | -$2.91M | -$60.16M | -$11.13M |
| EPS (Diluted) | n/a | n/a | -$0.04 | -$0.02 |
| Operating cash flow | -$14.11M | -$1.83M | -$44.76M | -$789.1K |
| Free cash flow | n/a | n/a | -$46.27M | -$794.6K |
| Cash & equivalents | $7.80M | $2.85M | $3.04M | $1.8K |
| Total assets | $12.96M | $2.93M | $81.29M | $7.02M |
| Total liabilities | $28.89M | $1.10M | $128.86M | $37.17M |
| Shareholders' equity | -$15.94M | $1.83M | -$60.28M | -$30.15M |
| Return on year-end equity | n/a | -158.8% | n/a | n/a |
| Shares outstanding | 31.73M | 3.18M | 1.56B | 662.50M |
Revenue, most recent five fiscal years
| Fiscal year | NRX Pharmaceuticals, Inc. | Avenue Therapeutics, Inc. | Northwest Biotherapeutics Inc | Cannapharmarx, Inc. |
|---|---|---|---|---|
| Latest | $1.45M Ended 2025-12-31 | $1.40M Ended 2025-12-31 | $1.38M Ended 2025-12-31 | $1.36M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $0 Ended 2024-12-31 | $1.38M Ended 2024-12-31 | $820.1K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | n/a | $1.93M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $1.68M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.00M Ended 2021-12-31 | $0 Ended 2021-12-31 |